2HQ0 Stock Chart & Stats
€3.75
€0.07(1.68%)
At close: 4:00 PM EDT
€3.75
€0.07(1.68%)
Day’s Range― - ―
52-Week Range€2.61 - €13.34
Previous CloseN/A
Volume5.87K
Average Volume (3M)2.74K
Market Cap
€398.70M
Enterprise Value€743.22M
Total Cash (Recent Filing)€218.01M
Total Debt (Recent Filing)€371.93M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Jan 11, 2027EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding147,787,520
10 Day Avg. Volume1,333
30 Day Avg. Volume2,739
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.38
Price to Sales (P/S)0.67
P/FCF Ratio-6.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.50Price Target Upside20.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.52
Revenue Forecast (FY)€979.34M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross-Profit GrowthRecord quarterly revenue and gross-profit growth, alongside a wider gross margin, indicates stronger recent operating traction across the portfolio. If sustained, improved scale and mix can support reinvestment and provide a more durable path toward the reaffirmed EBITDA target, even though profitability is not yet established.
Global Scale And InfrastructureA broad international footprint, substantial cultivation capacity, and end-to-end operating infrastructure give Tilray a platform across multiple regulated markets. This scale can support product availability, market expansion, and operating leverage as medical cannabis demand develops internationally.
Manageable Leverage And Debt ReductionRelatively conservative leverage provides more financial flexibility than a heavily indebted balance sheet, while principal reductions can lower future obligations. This support is important as management works to fund growth initiatives and improve profitability without relying entirely on additional borrowing.
Bears Say
Persistent UnprofitabilityTilray has improved from earlier periods of much larger losses, but it still lacks consistent profitability and is not earning an adequate return on its capital base. Continued losses limit internally funded growth and leave execution dependent on further operational improvement.
Ongoing Cash BurnNegative operating and free cash flow indicate that Tilray’s current operations are consuming cash rather than funding the business. Even with free cash flow less negative than in the prior annual period, continued burn can constrain investment capacity and increase reliance on financing or asset-level actions.
Beverage Portfolio And Distribution PressureWeakness in the legacy U.S. craft beverage portfolio shows that recent beverage growth is not uniformly broad-based and benefits materially from BrewDog. Ongoing brand rationalization and a challenging category can pressure revenue continuity, distribution reach, and the sustainability of segment margins.
2HQ0 FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was €2.61 and its highest was €13.34 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is €398.70M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Jan 11, 2027 which is in 80 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Oct 08, 2026. The company reported -€0.286 earnings per share for the quarter, missing the consensus estimate of -€0.162 by -€0.124.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is -0.14.
How many shares outstanding does Tilray have?
Tilray has 147,787,520 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -€0.286 in its last earnings report, missing expectations of -€0.162. Following the earnings report the stock price went down -5.689%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in DE:2HQ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.50 (20.09% Upside)
€4.50 (20.09% Upside)
Blogger Sentiment
Bullish
DE:2HQ0 Sentiment 62%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth €61.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.27%
12-Months-Change
Fundamentals
Return on Equity
-9.38%
Trailing 12-Months
Asset Growth
11.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
2HQ0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive. Tilray reported record revenue and gross profit, expanding consolidated and cannabis margins, strong international cannabis and BrewDog growth, U.S. craft beer brand momentum, debt reduction, and reaffirmed fiscal 2027 adjusted EBITDA guidance. These strengths were partly offset by a $40 million net loss, lower adjusted EBITDA, total cannabis revenue contraction, international price compression, Canadian adult-use headwinds, fuel costs, higher investment costs, and continued regulatory and market uncertainty.View all DE:2HQ0 earnings summaries2HQ0 Stock 12 Month Forecast
Average Price Target
€4.50
▲(20.09% Upside)











